What we do

Invicol is a specialized medical technology company focused on the development and production of a medical device.

The minimal invasive approach

Invicol GmbH is a biotech start-up located in the CoLaborator of the Bayer AG in Berlin, where we are developing the BMProbe. The Probe is inserted into the patients cubital vein for the isolation of rare circulating cells. The minimal invasive approach has a high sensitivity and specificity providing compelling and improved diagnostic value. Our technology opens new possibilities in the field of personalized medicine, early diagnosis and disease monitoring. 

The <strong>minimal invasive</strong> approach

Projects

Development of an innovative medical device for in vivo isolation of circulating endothelial cells

The aim of this project is an optimization of the Probes’ geometry and the validation of the functionality of the BMProbe. An optimized Probe geometry increases the blood volume that is screened by the Probe during its application. This joint project will be cofinanced within the framework by the IBB Pro Fit and European Regional Development Fund.

Funding Program: Pro FIT Projektfinanzierung
Funded by: EFRE
Project duration: 01.07.2018 – 31.12.2020
Cooperation partners: Beuth Hochschule für Technik und Charité – Universitätsmedizin Berlin

Development of an innovative medical device for <i>in vivo</i> isolation of <strong>circulating endothelial cells</strong>

Development of an innovative medical device for in vivo isolation of circulation tumor cells

The aim of this project is the development for an in vivo approach to isolate CTCs from the peripheral blood stream. The main claim ist to enrich sufficiently CTCs onto the Probe for a successful diagnostic tool.

This joint project will be cofinanced within the framework by the IBB Pro Fit and European Regional Development Fund. Together with the Biofluid Mechanics Lab of the Charité Berlin and the University of Potsdam.

Funding Program: Pro FIT Projektfinanzierung
Funding by: EFRE
Project duration: 01.01.2020 – 30.10.2022
Cooperation partner: Charité – Universitätsmedizin Berlin and University of Potsdam

Development of an innovative medical device for <i>in vivo</i> isolation of <strong>circulation tumor cells</strong>

Introducing the BM Probe

In contrast to many available products that are based on in vitro methodology the BMProbe isolates cells in vivo. The BMProbe is inserted into the patients’ cubital vein through a catheter or indwelling line. This means that in most cases, no additional punctuation is necessary.

The geometry of the BMProbe was optimized to screen the largest possible volume of blood in the cubital vein. Especially for the isolation of circulating tumor cells this has the potential to detect Circulating Tumor Cells (CTCs) before liquid biopsies can.  

Once the BMProbe is withdrawn, the number of isolated cells can be determined in just over an hour. This procedure is semi-automated and requires little training. Using the BMProbe, downstream molecular diagnostics are possible.

 

Circulating Endothelial Cells:  

Endothelial cells provide the physical interface between blood and surrounding tissue. They regulate nutrient and blood component traffic. Due to mechanical or chemical reactions Endothelial Cells can detach and enter the blood stream. They are then referred to as circulating endothelial cells (CECs). CECs are low in healthy patients (4 CEC/ml) and increased in patient with Acute Conorary Artery Disease or Heart Failure patients, among others. CECs are therefore considered to be a biomarker to monitor arterial plaque disruption and treatment response.  

 

Circulating Tumor Cells: 

Circulating Tumor Cells (CTCs) represent a proven diagnostic and prognostic indicator of disease progression. They disintegrate very early from the primary tumor and travel via the blood stream to all parts of the body. This enables an earlier detection of the tumor than by using imaging technology. As is well known, the earlier the cancer is diagnosed, the more likely that it can be effectively treated. Isolating and counting the CTCs using the BMProbe has the potential to improve the effectiveness of treatment.  

Team

Gabi Wendt

Gabi Wendt
Managing Director, Head of R&D

Paul Geus

Paul Geus
Managing Director, Head of Clinical Trial

Klaus Lücke, Ph.D.

Klaus Lücke, Ph.D.
Business Developer

Olga Babosova, Ph.D.

Olga Babosova, Ph.D.
Molecular Biologist

Magdalena Mayer, Ph.D.

Magdalena Mayer, Ph.D.
Clinical Research

Maike Hinnerkort

Maike Hinnerkort
Technical Assistant – R&D

Alexander Quedenau

Alexander Quedenau
Student Assistant

Peter Scharfschwerdt

Peter Scharfschwerdt
Technical Assistant – Production

Nina Baar

Nina Baar
Research Assiociate

Ernst Wellnhofer, PD Dr. med

Ernst Wellnhofer, PD Dr. med
Consultant – Clinical Trial